Forskning ved Københavns Universitet - Københavns Universitet

Forside

A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial

Publikation: Bidrag til tidsskriftTidsskriftartikel

  • Kastrup, Jens
  • Erik Jørgensen
  • Shmuel Fuchs
  • Sigrid Nikol
  • Hans Erik Bøtker
  • Mariann Gyöngyösi
  • Dietmar Glogar
  • Ran Kornowski
Genes encoding vascular endothelial growth factor (VEGF) can potentially augment myocardial perfusion in patients with coronary artery disease (CAD). We conducted a randomised, double-blind, placebo-controlled gene therapy study with the adenovirus carrying VEGF121 (BIOBYPASS [AdGVVEGF121.10NH]).
OriginalsprogEngelsk
TidsskriftEuroIntervention
Vol/bind6
Udgave nummer7
Sider (fra-til)813-8
Antal sider6
ISSN1774-024X
DOI
StatusUdgivet - 2011

ID: 40168461